Author:
Talbot D C,Moiseyenko V,Van Belle S,O'Reilly S M,Alba Conejo E,Ackland S,Eisenberg P,Melnychuk D,Pienkowski T,Burger H-U,Laws S,Osterwalder B
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Aapro M (2000) First-line capecitabine treatment for metastatic breast cancer (MBC): updated data from a randomised phase II trial. Proceedings from 10th International Congress on Anti-Cancer Treatment Paris (abstract S4–10)
2. Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075–1107
3. Blum JL (1999) Xeloda® in the treatment of metastatic breast cancer. Oncology 57(Suppl. 1): 16–20
4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999a) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493
5. Blum JL, Buzdar AU, Dieras V, LoRusso PM, Rutman O, Curtiss K, Thibault A, Griffin T (1999b) A multicenter phase II study of XelodaTM (capecitabine) in taxane-refractory metastatic breast cancer. (abstract) Proc Am Soc Clin Oncol 18: 107a (abstract 403)